Effect of Empagliflozin 10 vs 25 mg on LV Remodeling in Diabetic Patients With Anterior STEMI With Reduced LVEF

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.

Also called NCT07169981

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 200 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT07169981
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT07169981. Randomized; double masking; primary purpose treatment. Start 2023-07-12 (actual); primary completion 2025-02-23 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Empagliflozin 10 vs 25 mg on LV Remodeling in Diabetic Patients With Anterior STEMI With Reduced LVEF
Acronym
EMPA-DMMI
Condition
Diabete Mellitus
Condition
Heart Failure
Condition
Remodeling, Left Ventricle
Intervention (Drug)
Empagliflozin 10 MG [Jardiance]
Intervention (Drug)
empagliflozin (Jardiance) 25 mg
Lead sponsor
Ain Shams University (class: other)

Record details

Record id
cardio:ct-nct07169981
Content hash
41e75ebcfb76b008d4de956c574615de946613acb4d569f0b6d3ab52206dbfdc